e-learning
resources
Copenhagen 2005
Monday 19.09.2005
Advancements in diffuse parenchymal lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety and efficacy of prolonged treatment of fibrosing alveolitis in scleroderma with cyclophosphamide
S. Dass, C. Fernandes, B. Griffiths, P. Emery, M. T. Henry (Leeds, United Kingdom)
Source:
Annual Congress 2005 - Advancements in diffuse parenchymal lung disease
Session:
Advancements in diffuse parenchymal lung disease
Session type:
Poster Discussion
Number:
1798
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Dass, C. Fernandes, B. Griffiths, P. Emery, M. T. Henry (Leeds, United Kingdom). Safety and efficacy of prolonged treatment of fibrosing alveolitis in scleroderma with cyclophosphamide. Eur Respir J 2005; 26: Suppl. 49, 1798
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids
Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Year: 2009
Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
Source: Eur Respir J 2005; 25: 528-533
Year: 2005
Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 268s
Year: 2005
Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Treatment of exacerbations of fibrotic idiopathic interstitial pneumonias with cyclophosphamide and corticosteroids
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2010
A 12-week combination of clarithromycin and prednisone for the treatment of cryptogenic and radiation-induced organising pneumonia
Source: International Congress 2015 – New insights into IIPs
Year: 2015
Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004
Safety of corticosteroid therapy in patients with pulmonary sarcoidosis
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017
High-dose inhalation corticosteroids in conjunction with plasmapheresis in the treatment of patients with acute variant of exogenic allergic alveolitis (EAA)
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis
Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017
Year: 2017
Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Hypersensitivity pneumonitis associated with the use of temozolomide
Source: Eur Respir J 2009; 33: 931-934
Year: 2009
Rituximab in the treatment of refractory pulmonary sarcoidosis
Source: Eur Respir J 2014; 43: 1525-1528
Year: 2014
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses
Source: Eur Respir J 2011; 38: 1487-1489
Year: 2011
High-dose acetylcysteine in idiopathic pulmonary fibrosis
Source: ISSN=ISSN 1810-6838, ISBN=, page=358
Year: 2006
Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia
Source: Eur Respir J 2015; 45: 1624-1631
Year: 2015
Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease
Source: International Congress 2017 – Novel and old entities
Year: 2017
Combination of pentoxifylline and steroids in sarcoidosis treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 269s
Year: 2005
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept